These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease.
    Author: Zhou L, Chen H, Wen Q, Zhang Y.
    Journal: Eur J Gastroenterol Hepatol; 2012 Jun; 24(6):695-701. PubMed ID: 22387885.
    Abstract:
    OBJECTIVE: The study is carried out to identify the expression pattern of indoleamine 2,3-dioxygenase (IDO) in human Crohn's disease and ulcerative colitis and to investigate the effect of different therapies (salicylates, steroids, and antitumor necrosis factor antibody) on the intestinal expression of IDO. METHODS: Immunohistochemistry was used. A total of 10 high power fields were counted for each patient. RESULTS: IDO was expressed in the both lamina propria and epithelium. IDO expression increased in the lesions from ulcerative colitis and Crohn's disease and was positively related to the severity of inflammation. IDO-positive mononuclear cells also expressed CD11c, CD68, and TLR4. IDO expression decreased significantly after treatment with steroids and salicylates, but remained unchanged after infliximab therapy. CONCLUSION: IDO was over-expressed in human inflammatory bowel disease. It may be a bridge between innate immunity and adaptive immunity. Steroids and salicylates may act through the inhibition of IDO expression. IDO upregulation may be a promising therapy to achieve inflammatory bowel disease remission.
    [Abstract] [Full Text] [Related] [New Search]